PT Etana Biotechnologies Indonesia has officially introduced two new cancer treatment drugs—Etapidi (tislelizumab) and Brukinsa (zanubrutinib)—marking a significant milestone in the country’s healthcare landscape. The launch, announced in April 2025, is the result of a strategic collaboration with global biopharmaceutical giant BeiGene.
According to local reports, both medications have received official distribution permits in Indonesia. Etapidi was approved on November 26, 2024 (NIE DKI2468600149A1), while Brukinsa received approval on September 20, 2024 (NIE DKI2468000201A1). The launch was highlighted by the Etana Oncology Summit, a dedicated forum aimed at enhancing collaboration between the biopharmaceutical industry and medical professionals to improve cancer care across the country.
Nathan Tirtana, CEO of Etana, described the launch as a significant step in the company’s mission to provide innovative cancer therapies within Indonesia.
“We believe the arrival of Etapidi and Brukinsa offers new hope for cancer patients in Indonesia by delivering cutting-edge therapies that are globally recognized yet accessible and affordable locally,” he said in an official statement.
Two Targeted Cancer Treatments Now Available in Indonesia
Etapidi (tislelizumab) is a humanized IgG4 monoclonal antibody designed for the treatment of non-small cell lung cancer and esophageal squamous cell carcinoma. It is administered as an intravenous infusion. Brukinsa (zanubrutinib), on the other hand, is a Bruton’s Tyrosine Kinase (BTK) inhibitor indicated for the treatment of mantle cell lymphoma and Waldenström’s macroglobulinemia. It is available in capsule form, providing greater ease of use for patients.
Etana’s partnership with BeiGene is more than just a product launch—it represents a shared commitment to expanding access to affordable, innovative cancer therapies throughout Indonesia. The collaboration is also expected to accelerate research and development efforts, enabling the creation of cost-effective solutions for cancer patients not just locally, but globally.
“We are deeply grateful for the dedication of doctors and healthcare professionals who are on the front lines of diagnosing and supporting patients,” Tirtana added.
A Major Leap in Cancer Treatment Accessibility
The availability of Etapidi and Brukinsa signals a meaningful advancement in cancer treatment within Indonesia. Both drugs offer new therapeutic approaches that have shown efficacy in various clinical trials. With these options, there is renewed optimism for improving treatment success rates and enhancing the quality of life for cancer patients across the country.
Etapidi works by targeting cancer cells specifically, thereby reducing damage to healthy cells and minimizing the side effects often associated with traditional chemotherapy. Brukinsa, as a BTK inhibitor, blocks key signals that cancer cells need to grow, offering a more precise and tolerable treatment option.
The Etana Oncology Summit, held alongside the product launch, served as a vital platform for knowledge exchange in the field of oncology. It brought together experts, researchers, and healthcare professionals to discuss the latest developments in cancer care and explore ways to strengthen collaboration for better patient outcomes.
Etana’s ongoing dedication to increasing access to innovative therapies is evident in its alliance with BeiGene. This partnership not only brings state-of-the-art cancer treatment technologies to Indonesia but also reinforces the company’s mission to make effective cancer care more affordable and widely available.
